Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.

Mirati raises $300m as its chief exec departs. What’s not to like?